CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Does the Evidence Support the Hype Around Antiviral Treatments for COVID-19?

May 27, 2020
Media Advisory Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies. Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...

Patient Input and Clinical Experts: Zolgensma

May 26, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Zolgensma Generic name onasemnogene abeparvovec Manufacturer Novartis Pharmaceuticals Canada Inc. Indication(s) Spinal muscular atrophy (SMA), pediatrics Project Number SG0649-000 Call for pat...

CADTH Board of Directors Names Suzanne McGurn as Next President and CEO

May 19, 2020
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020. Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...